Bexmarilimab

Phase 2Monoclonal antibody

FFaron Pharmaceuticals Ltd

Bexmarilimab is one of 43 small molecule programs targeting Colon Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colon CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Higher-Risk Myelodysplastic SyndromesNot yet recruiting

Colon CarcinomaPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Higher-Risk Myelodysplastic SyndromesPhase 2

Not yet recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Bexmarilimab

FFaron Pharmaceuticals Ltd

Phase 2

1 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

REGN2810

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Not yet recruiting

Metastatic Soft-Tissue Sarcoma

NCT07460986

Q4 2030

Phase 2Not yet recruiting

Higher-Risk Myelodysplastic Syndromes

NCT07672769

Clinical

Trials by Indication[1]

Hematological Malignancies1 trial

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Active, not recruiting·FFaron Pharmaceuticals Ltd·Phase 1/2·NCT05428969·181 enrolled

Metastatic Soft-tissue Sarcoma1 trial

A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA

Not yet recruiting·MMedSIR·Phase 1/2·NCT07460986·278 enrolled

Colon Carcinoma1 trial

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

Withdrawn·FFaron Pharmaceuticals Ltd·Phase 1/2·NCT05104905

Non-Small Cell Lung Cancer1 trial

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT05171062

Higher-risk Myelodysplastic Syndromes1 trial

Bexmarilimab Plus Azacitidine in a Randomized, Double-blind, Placebo-controlled Phase IIb Trial in Treatment-naïve Higher-risk Myelodysplastic Syndromes (HR-MDS)

Not yet recruiting·FFaron Pharmaceuticals Ltd·Phase 2·NCT07672769·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Bexmarilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bexmarilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bexmarilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faron Pharmaceuticals Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: FFaron Pharmaceuticals Ltd

Bexmarilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2030

Trials by Indication[1]

Hematological Malignancies1 trial

Metastatic Soft-tissue Sarcoma1 trial

Colon Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Higher-risk Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News